Table 1.
Proliferation of PBMC upon stimulation under different conditions. Proliferation of PBMC is expressed as a percentage increase in proliferation (%) with respect to non-induced controls
| Stimuli (µg/mL) | Mean (%) | Standard deviation (%) | ||||
|---|---|---|---|---|---|---|
| PMA | Ionomycin | PHA | Anti-CD3 | Anti-CD28 | ||
| 0.062 | 0.625 (0.08 µM) | 75.84 | 3.63 | |||
| 0.083 | 0.833 (0.11 µM) | 73.71 | 3.40 | |||
| 0.100 | 1.000 (0.13 µM) | 73.07 | 4.16 | |||
| 0.125 | 1.250 (0.17 µM) | 75.07 | 5.03 | |||
| 0.250 | 2.500 (0.33 µM) | 80.54 | 3.18 | |||
| 0.250 | 3.735 (0.50 µM) | 78.55 | 1.20 | |||
| 5 | 1.57 | 0.30 | ||||
| 10 | 12.27 | 2.41 | ||||
| 20 | 42.34 | 2.87 | ||||
| 0.1 | 0.1 | 30.57 | 0.53 | |||
| 0.4 | 0.4 | 53.90 | 3.20 | |||
| 1 | 1 | 59.84 | 0.75 | |||
PBMC peripheral blood mononuclear cells; PHA phytohemagglutinin; PMA phorbol myristate acetate